AstraZeneca PLC AZNCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AstraZeneca's Experimental Cancer Drug Misses Target in Pivotal Trial — Update
-
AstraZeneca's Breast Cancer Drug Missed Targets in Phase Three Trial
-
MedImmune Receives FDA Approval for Self-Administered Flu Vaccine
-
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
-
AstraZeneca Employees Detained in China Over Alleged Data, Drug-Import Violations — Update
-
AstraZeneca Employees Detained in China Over Data and Drug-Import Scrutiny
-
5 things you need to know about COVID, flu and RSV vaccines this fall
-
AstraZeneca's Imfinzi Wins FDA Priority Review to Treat Limited-Stage Small Cell Lung Cancer
Trading Information
- Previous Close Price
- $152.80
- Day Range
- $152.66–155.18
- 52-Week Range
- $118.16–175.00
- Bid/Ask
- $149.09 / $160.66
- Market Cap
- $236.67 Bil
- Volume/Avg
- 590 / 1,796
Key Statistics
- Price/Earnings (Normalized)
- 21.14
- Price/Sales
- 4.85
- Dividend Yield (Trailing)
- 1.95%
- Dividend Yield (Forward)
- 1.95%
- Total Yield
- 1.95%
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 89,900
- Website
- https://www.astrazeneca.com
Competitors
Valuation
|
Metric
|
AZNCF
|
LLY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.14 | 79.49 | 20.96 |
Price/Book Value | 5.99 | 58.90 | 1.85 |
Price/Sales | 4.85 | 20.60 | 2.90 |
Price/Cash Flow | 22.49 | 79.87 | 21.18 |
Price/Earnings
AZNCF
LLY
PFE
Financial Strength
|
Metric
|
AZNCF
|
LLY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.69 | 0.61 | 0.51 |
Current Ratio | 0.89 | 1.11 | 0.86 |
Interest Coverage | 5.45 | 15.08 | −0.88 |
Quick Ratio
AZNCF
LLY
PFE
Profitability
|
Metric
|
AZNCF
|
LLY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 57.63% | 13.15% | 3.50% |
Return on Equity (Normalized) | 151.23% | 69.16% | 8.28% |
Return on Invested Capital (Normalized) | 84.88% | 23.97% | 5.39% |
Return on Assets
AZNCF
LLY
PFE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Npbjmxbsz | Xsf | $798.8 Bil | |||
| Johnson & Johnson
JNJ
| Vcdkmhr | Jbnj | $385.9 Bil | |||
| AbbVie Inc
ABBV
| Mvbqbplfb | Bnbqj | $343.2 Bil | |||
| Merck & Co Inc
MRK
| Dntqxbg | Hcpzy | $278.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Ktdqtmhcs | Knv | $244.4 Bil | |||
| AstraZeneca PLC ADR
AZN
| Tgbycbmbw | Vtpwh | $238.9 Bil | |||
| Novartis AG ADR
NVS
| Hyyhtjtqp | Syrk | $232.2 Bil | |||
| Amgen Inc
AMGN
| Yvcbwsfvv | Jhw | $171.8 Bil | |||
| Pfizer Inc
PFE
| Chpbbjzs | Pht | $162.0 Bil | |||
| Sanofi SA ADR
SNY
| Vrjzdpdmc | Ygbsl | $140.7 Bil |
United States